255 related articles for article (PubMed ID: 31806771)
1. Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for
Bakht MK; Lovnicki JM; Tubman J; Stringer KF; Chiaramonte J; Reynolds MR; Derecichei I; Ferraiuolo RM; Fifield BA; Lubanska D; Oh SW; Cheon GJ; Kwak C; Jeong CW; Kang KW; Trant JF; Morrissey C; Coleman IM; Wang Y; Ahmadzadehfar H; Dong X; Porter LA
J Nucl Med; 2020 Jun; 61(6):904-910. PubMed ID: 31806771
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of peptide-based imaging agents [
Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling.
White MA; Tsouko E; Lin C; Rajapakshe K; Spencer JM; Wilkenfeld SR; Vakili SS; Pulliam TL; Awad D; Nikolos F; Katreddy RR; Kaipparettu BA; Sreekumar A; Zhang X; Cheung E; Coarfa C; Frigo DE
Endocr Relat Cancer; 2018 Apr; 25(4):453-469. PubMed ID: 29431615
[TBL] [Abstract][Full Text] [Related]
5. Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells.
Sommer U; Siciliano T; Ebersbach C; Beier AK; Stope MB; Jöhrens K; Baretton GB; Borkowetz A; Thomas C; Erb HHH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162969
[TBL] [Abstract][Full Text] [Related]
6. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
[TBL] [Abstract][Full Text] [Related]
7. Development of
Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
9. Gene's expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study.
Bauckneht M; Marini C; Cossu V; Campi C; Riondato M; Bruno S; Orengo AM; Vitale F; Carta S; Chiola S; Chiesa S; Miceli A; D'Amico F; Fornarini G; Terrone C; Piana M; Morbelli S; Signori A; Barboro P; Sambuceti G
J Transl Med; 2023 Jan; 21(1):3. PubMed ID: 36600265
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation and Pilot Clinical Study of Al
Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Prostate-specific Membrane Antigen (PSMA/FOLH1) Expression in a Genomic Database.
Bahler CD; Johnson MM; Davicioni E; Zhang J; Cheng L; Green MA; Koch MO
Urology; 2020 Oct; 144():117-122. PubMed ID: 32619596
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
Kuroda K; Liu H
Int J Oncol; 2019 Apr; 54(4):1357-1366. PubMed ID: 30720063
[TBL] [Abstract][Full Text] [Related]
13. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of
Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.
Bakht MK; Derecichei I; Li Y; Ferraiuolo RM; Dunning M; Oh SW; Hussein A; Youn H; Stringer KF; Jeong CW; Cheon GJ; Kwak C; Kang KW; Lamb AD; Wang Y; Dong X; Porter LA
Endocr Relat Cancer; 2018 Nov; 26(2):131-146. PubMed ID: 30400059
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
[TBL] [Abstract][Full Text] [Related]
18. Sox7 negatively regulates prostate-specific membrane antigen (PSMA) expression through PSMA-enhancer.
Peng W; Guo L; Tang R; Liu X; Jin R; Dong JT; Xing CG; Zhou W
Prostate; 2019 Mar; 79(4):370-378. PubMed ID: 30488457
[TBL] [Abstract][Full Text] [Related]
19. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells.
Cao KY; Xu L; Zhang DM; Zhang XM; Zhang T; He X; Wang Z; Feng FS; Qiu SP; Shen GX
Int J Oncol; 2012 Jun; 40(6):1977-85. PubMed ID: 22322627
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
